Get the Stockscreener App
4.78
0.42%
0.02
Avalo Therapeutics Inc stock is traded at $4.78, with a volume of 92,801.
It is up +0.42% in the last 24 hours and up +32.04% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$4.76
Open:
$4.78
24h Volume:
92,801
Relative Volume:
1.34
Market Cap:
$52.19M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00135
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+3.02%
1M Performance:
+32.04%
6M Performance:
-42.62%
1Y Performance:
-63.79%
1-Day Range:
$4.55
$4.85
1-Week Range:
$4.50
$5.02
52-Week Range:
$3.39
$16.00
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
4.78 | 52.19M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
(AVTX) Long Term Investment Analysis - news.stocktradersdaily.com
Avalo Therapeutics appoints Dr. Rita Jain to board of directors By Investing.com - Investing.com Nigeria
Avalo Therapeutics (AVTX) Welcomes New Board Member | AVTX Stock News - GuruFocus
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - GlobeNewswire
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to B - GuruFocus
Avalo Therapeutics appoints Dr. Rita Jain to board of directors - Investing.com
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 45.8% in May - Defense World
AVTX Virtual Meeting Scheduled for June 23 by BTIG | AVTX Stock News - GuruFocus
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) PT at $30.00 - Defense World
Avalo Therapeutics Signs New Sales Agreement - TipRanks
Avalo Therapeutics Highlights AVTX-009 Potential in HS Market - TipRanks
Northern Trust Corp Invests $168,000 in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded at HC Wainwright - Defense World
H.C. Wainwright upgrades Avalo Therapeutics stock to buy - Investing.com
Avalo Therapeutics assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright upgrades Avalo Therapeutics stock to buy By Investing.com - Investing.com South Africa
AVTX: Avalo Therapeutics Receives Buy Rating with $15 Target Pri - GuruFocus
Avalo Therapeutics (AVTX) Receives Buy Rating from H.C. Wainwright | AVTX Stock News - GuruFocus
Cardax (OTCMKTS:CDXI) and Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Analysis - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics to Participate in Upcoming Investor Conferenc - GuruFocus
Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Tower Research Capital LLC TRC - Defense World
Strong Cash Position Secures AVTX Through 2027 | AVTX Stock News - GuruFocus
Avalo Therapeutics Reports Improved Financial Performance - TipRanks
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics reports Q1 EPS ($1.25) vs. ($141.14) last year - TipRanks
Avalo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
AVTX Advances Phase 2 LOTUS Trial, Targets 2026 Data | AVTX Stoc - GuruFocus
AVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly Earnings - Nasdaq
Avalo Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-Q Report - TradingView
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire Inc.
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Avalo Therapeutics Updates on AVTX-009 and LOTUS Trial - TipRanks
15,323 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Acquired by Marshall Wace LLP - Defense World
When the Price of (AVTX) Talks, People Listen - news.stocktradersdaily.com
Avalo Therapeutics Enters $75 Million Sales Agreement With TD Cowen For Common Stock Offering - marketscreener.com
Geode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 20.3% in March - Defense World
60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages - Defense World
Avalo Therapeutics (AVTX) Sees New Options Listings for April | AVTX Stock News - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
Advanced Cancer Pain Management Therapeutics Market Size in 7MM - openPR.com
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | Director |
Nov 12 '24 |
Buy |
12.50 |
500 |
6,250 |
500 |
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):